Pharmaceutical company Moderna, Inc., announced Thursday that it has completed its enrollment of 30,000 volunteers to participate in its final stage COVID-19 vaccine trial.
More than 25,600 participants have received a second shot of the vaccine candidate, mRNA-1273, according to Moderna.
The company released the makeup of the volunteers. More than a third of the participants come from communities of color. Fifty-three percent of the volunteers are male, and more than 14,000 are female.
Eight thousand study participants are currently living with chronic diseases.
The company says that it expects an initial readout on whether the vaccine is effective by late November. If the vaccine is found to be effective, the company would submit an emergency-use application request to the U.S. Food and Drug Administration.
Moderna’s mRNA-1273 is made from messenger ribonucleic acid (mRNA), “a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies to fight the virus,” the company’s website explains.
The FDA requires a company to provide at least two months of follow-up data from a completed vaccine trial study regime before it will review an application for emergency use authorization of an experimental vaccine.
More coronavirus pandemic coverage:
Cox Media Group